Phase Forward's income drops in Q2

By Nick Taylor

- Last updated on GMT

Related tags Phase forward Clinical research Generally accepted accounting principles

Phase Forward’s GAAP net income fell by 41 per cent in Q2 despite an increase in revenues, as rising operating costs hit the company.

The eClinical business’ net income slipped to $2.2m (€1.5m), compared with $3.7m the previous year, primarily because of a leap in operating costs.

Phase Forward’s costs rose by 46 per cent to $27.4m, taking total operating expenses for the year over $50m. Generally accepted accounting practice (GAAP) operating income for the quarter was $4.2m, down 26 per cent on the previous year.

Despite these difficulties Phase Forward believes the results were better than expected, with the company buoyed by revenues that rose by 29 per cent to $52.5m.

Bob Weiler, Phase Forward’s CEO, viewed this as evidence that the business is equipped to meet clients’ demands.

He commented: “Customers are increasingly looking for a broader, end-to-end, integrated clinical research suite (ICRS) from a single, trusted vendor. We believe that Phase Forward has the broadest and deepest ICRS offering in the market place​.”

In addition, Phase Forward has renewed and extended contracts with existing clients and continued to push its InForm electronic data capture (EDC) software.

GlaxoSmithKline (GSK) and INC Research have both recently signed deals to use InForm, joing a number of other pharma companies and contract research organisations (CRO) that use the software.

Phase Forward’s share price rose slightly by the end of trading yesterday, having dipped earlier in the day.

Maaguzi acquisition

Phase Forward has acquired Maaguzi, a provider of web-based electronic patient reported outcomes (ePRO), for $11m. The purchase extends the company’s ICRS and moves it into the ePRO market, which it views as being increasingly important.

Maaguzi also markets Outcome Logix. This can be used for late-phase, observational studies and collates investigator-collected data and patient-reported data into a single web-based system.

Phase Forward also acquired Covance’s interactive voice and web response services earlier this month.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us

Products

View more

Webinars